

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 75345

**Title:** Loss of HE Y in HE Y+ breast cancer after neoadjuvant treatment: Case report and literature review

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06254068

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Somalia

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-01-25

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-01-26 10:27

**Reviewer performed review:** 2022-01-28 17:24

**Review time:** 2 Days and 6 Hours

|                    |   |
|--------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| Language quality   | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion         | <input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority)<br><input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| Re-review          | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

|                                     |   |
|-------------------------------------|---|
| <b>Peer-reviewer<br/>statements</b> | Peer-Review: [ <input type="checkbox"/> ] Anonymous [ <input checked="" type="checkbox"/> ] Onymous<br>Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No |
|-------------------------------------|---|

#### **SPECIFIC COMMENTS TO AUTHORS**

-The manuscript text is lacking spaces bewtween words and sentences. -Final Conclusion is missing after the discussion -After the abstract, there are paragraphs with no Heading (is INTRODUCTION missing?) -

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 75345

**Title:** Loss of HE in HE + breast cancer after neoadjuvant treatment: Case report and literature review

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03723209

**Position:** Editorial Board

**Academic degree:** FRCS (Ed), FRCS (Gen Surg)

**Professional title:** Assistant Professor, Doctor

**Reviewer's Country/Territory:** Singapore

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-01-25

**Reviewer chosen by:** Xin Liu (Online Science Editor)

**Reviewer accepted review:** 2022-03-08 01:39

**Reviewer performed review:** 2022-03-08 01:53

**Review time:** 1 Hour

|                    |   |
|--------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| Language quality   | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion         | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority)<br><input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| Re-review          | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No   |

|                                     |   |
|-------------------------------------|---|
| <b>Peer-reviewer<br/>statements</b> | Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous<br>Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No |
|-------------------------------------|---|

#### **SPECIFIC COMMENTS TO AUTHORS**

This is a well written case report describing the loss of Her2 amplification in a patient with breast cancer after neoadjuvant chemotherapy and the authors went on to do a literature review of this phenomenon which has been shown in about 10% of patient in case series. Just a small point i would like the authors to clarify is with regards to the take home message, i think in this patient she continued to complete herceptin even after the her2 loss of amplification, so is the take home message that patient should continue to be treated based on initial her2 status pre neoadjuvant chemotherapy? I believe this point will be useful for readers if it is more explicitly clarified or stated.